07:00 , May 12, 2014 |  BioCentury  |  Strategy

Good news for dealmakers

While Merck & Co. Inc. continues its stepwise downsizing, the pharma is sending signals that the welcome mat is out for BD&L deals. The pharma made good on its plan to seek alternatives for its...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Ariad, Merck deal

Ariad disclosed in its 4Q13 and 2013 earnings that partner Merck is terminating an amended 2007 deal under which the pharma had exclusive, worldwide rights to develop and commercialize ridaforolimus for cancer indications. The termination...
08:00 , Mar 3, 2014 |  BioCentury  |  Finance

Watchful waiting

Watchful waiting On paper, activist investor Alex Denner already has doubled his money on Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), but his recent addition to the company's board suggests he sees even more value to be unlocked....
01:30 , Feb 26, 2014 |  BC Extra  |  Company News

Merck terminating Ariad ridaforolimus deal

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) disclosed in its 4Q13 and 2013 financial results on Tuesday that partner Merck & Co. Inc. (NYSE:MRK) is terminating an amended 2007 deal under which the pharma had exclusive, worldwide rights...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

NIRsupreme Ridaforolimus-Eluting Coronary Stent System: Phase II started

Medinol began the single-blind, international Phase II BIONICS trial to compare NIRsupreme Ridaforolimus-Eluting Coronary Stent System vs. Endeavor Resolute Zotarolimus-Eluting Stent in about 1,900 patients. The start of the trial - along with the start...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Clinical News

NIRsupreme Ridaforolimus-Eluting Coronary Stent System: Phase II started

Medinol began the single-blind, international Phase II NIREUS trial to compare NIRsupreme Ridaforolimus-Eluting Coronary Stent System vs. Endeavor Resolute Zotarolimus-Eluting Stent in about 300 patients. The start of the trial - along with the start...
07:00 , Oct 14, 2013 |  BioCentury  |  Strategy

Reviving Merck

As Merck & Co. Inc. 's new head of R&D, Roger Perlmutter plans to refocus and prune the pharma's pipeline of 31 Phase II and Phase III programs. But with half of its Phase III...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

4Q Stock Wrap-Up: Go big or go home

Large cap biotechs were the only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26% gain on the year. Small caps brought up the rear in 4Q, but...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

Taltorvic ridaforolimus regulatory update

EMA's CHMP provided a list of questions and answers related to a withdrawn MAA from Merck for ridaforolimus as maintenance therapy for patients with soft tissue sarcoma or primary malignant bone tumor. CHMP said that...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

Taltorvic ridaforolimus regulatory update

Merck withdrew an MAA in the EU for ridaforolimus as maintenance therapy for patients with soft tissue sarcoma or primary malignant bone tumor. According to the pharma, EMA's CHMP said based on a "provisional view"...